Shopping Cart

Your shopping cart is currently empty

ALC-0315

Name: ALC-0315
Brand: TargetMol
SKU: T9277
Price: 30 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

🥰Excellent

Hot

Synonyms:

Catalog No. T9277 Copy Product Info

Purity: 99.66%

🥰Excellent

Hot

ALC-0315 is an ionizable cationic lipid that serves as a core component of lipid nanoparticle (LNP) delivery systems for mRNA vaccines, responsible for efficiently encapsulating, protecting, and delivering nucleic acids into cells. Lipid nanoparticles have already been used in research on mRNA (COVID-19) vaccines.

Cas No. 2036272-55-4

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
1 mg	$30	-	In Stock
5 mg	$57	In Stock	In Stock
10 mg	$78	-	In Stock
25 mg	$121	In Stock	In Stock
50 mg	$173	In Stock	In Stock
100 mg	$255	In Stock	In Stock
200 mg	$377	-	In Stock

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.66%

Color:Transparent

Resource Download

COA HNMR MS

Product Introduction

Bioactivity

Description	ALC-0315 is an ionizable cationic lipid that serves as a core component of lipid nanoparticle (LNP) delivery systems for mRNA vaccines, responsible for efficiently encapsulating, protecting, and delivering nucleic acids into cells. Lipid nanoparticles have already been used in research on mRNA (COVID-19) vaccines.
In vitro	Methods: Primary HSCs were isolated from mouse livers. After 2 hours of plating, cell lysates were collected for RNA extraction. One week after LNP-siRNA injection, HSCs were isolated, and target gene mRNA levels were detected by qPCR. Results: ALC-0315 LNP achieved stronger gene silencing in HSCs compared to MC3 LNP. [1]
In vivo	Methods: LNPs encapsulating different siRNAs (targeting FVII [hepatocytes] or ADAMTS13 [HSCs], or control siLuc) were administered via tail vein injection at doses of 1 mg/kg siRNA (standard silencing dose) or 5 mg/kg siRNA (high dose for toxicity assessment). Animals were euthanized 1 week after dosing, and blood and liver tissue were collected for analysis. Results: Hepatocyte silencing (FVII): At a dose of 1 mg/kg, the knockdown effect of ALC-0315 LNP on plasma FVII protein levels was approximately twice that of MC3 LNP. Hepatic stellate cell silencing (ADAMTS13): at a dose of 1 mg/kg, the inhibitory effect of ALC-0315 LNP on plasma ADAMTS13 activity was approximately 10 times that of MC3 LNP. [1] Methods: Female BALB/c mice were selected and received intramuscular (IM) injections of ALC0315-DNA, ALC0315-RNA, or an empty LNP control into both tibialis anterior muscles. Imaging was performed at 6 h, 24 h, 48 h, 72 h, 7 d, 14 d, 21 d, and 28 d. Results: The signal intensity of RNA-LNP was significantly higher than that of DNA-LNP. The expression duration of ALC0315-DNA was >28 days, while that of ALC0315-RNA was 21 days.[2]

Chemical Properties

Molecular Weight	766.27
Formula	C₄₈H₉₅NO₅
Cas No.	2036272-55-4
Smiles	CCCCCCCCC(CCCCCC)C(=O)OCCCCCCN(CCCCO)CCCCCCOC(=O)C(CCCCCC)CCCCCCCC
Relative Density.	0.919 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Keep away from direct sunlight Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 100 mg/mL (130.5 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (5.22 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.3050 mL	6.5251 mL	13.0502 mL	65.2512 mL
5 mM	0.2610 mL	1.3050 mL	2.6100 mL	13.0502 mL
10 mM	0.1305 mL	0.6525 mL	1.3050 mL	6.5251 mL
20 mM	0.0653 mL	0.3263 mL	0.6525 mL	3.2626 mL
50 mM	0.0261 mL	0.1305 mL	0.2610 mL	1.3050 mL
100 mM	0.0131 mL	0.0653 mL	0.1305 mL	0.6525 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 µL Tween 80 and mix well until fully clarified.

3) Add 450 µL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc